To help ensure the highest level of patient safety and research quality, the Cancer Therapy and Research Center (CTRC) at The University of Texas Health Science Center at San Antonio (UTHSCSA) Protocol Review Committee (PRC) is charged with the responsibility for internal oversight of the scientific and research aspects of all cancer clinical trials at the CTRC at UTHSCSA. The PRC helps to ensure that the Cancer Center's Shared Resources are engaged appropriately to facilitate the best possible study conduct and to maximize the overall scientific productivity of the Cancer Center. The primary PRC function is to review all studies for scienfific merit, to ensure prioritizafion of protocols according to P30 scienfific priorifies, and to monitor study progress for all cancer-related prevenfion and therapeufic clinical research protocols. The Chair of the PRC reports to the P30 Deputy Director. The P30 Office of Research Administrafion (ORA) is a Cancer Center shared resource which provides support to the PRC. The funcfion of the PRC is complementary to that of the UTHSCSA Insfitufional Review Board (IRB), which focuses on the protecfion of human subjects. All stipulafions identified by the PRC must be resolved prior to IRB submission. PRC funcfions do not duplicate or overiap with the responsibilifies of the IRB, nor does the PRC perform either auditing or data and safety monitoring functions which are performed in the CTRC by the ORA and the Data Safety and Monitoring Committee (DSMC) respecfively. The PRC is responsible for pre-acfivation and study continuafion activities related to scientific areas of research. All cancer-related studies involving the use of human subjects require the initial approval of this PRC prior to submission to the UTHSCSA IRB. The PRC has the authority to open protocols (with IRB approval) that demonstrate scientific merit and that meet the priorities of the P30. The PRC can close protocols that do not show sufficient scienfific progress or accrual. All studies, at time of inifial review are assigned a priority of audit level score (PALS) in a joint process between the PRC and DSMC. The Data Safety Officer (DSO), who is a member of both the PRC and DSMC, coordinates this process. A study PALS is then entered into the IDEAS database by the DSO. This score is used to determine the trial's overall likelihood of being audited by the DSO and the audit team. Approval of a protocol by PRC is a fundamental requirement, as is IRB approval, to allow performance of a cancer-related protocol by CTRC at UTHSCSA members within the affiliated institutions of the CTRC at UTHSCSA.

Public Health Relevance

The PRC is crifically important to the Cancer Center's research because of its pivotal role in ensuring that all new protocols opened at the CTRC at UTHSCSA are scientifically sound and are prioritized in terms of Shared Resource ufilizafion which facilitates best possible study conduct and maximizes the overall scientific producfivity of the Cancer Center.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA054174-19
Application #
8320971
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
2014-07-31
Budget Start
2011-08-01
Budget End
2013-07-31
Support Year
19
Fiscal Year
2011
Total Cost
$22,670
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Type
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Deng, Yilun; Qin, Yuejuan; Srikantan, Subramanya et al. (2018) The TMEM127 human tumor suppressor is a component of the mTORC1 lysosomal nutrient-sensing complex. Hum Mol Genet 27:1794-1808
Wei, Zhen; Panneerdoss, Subbarayalu; Timilsina, Santosh et al. (2018) Topological Characterization of Human and Mouse m5C Epitranscriptome Revealed by Bisulfite Sequencing. Int J Genomics 2018:1351964
Chiang, Huai-Chin; Zhang, Xiaowen; Zhao, Xiayan et al. (2018) Gene-Specific Genetic Complementation between Brca1 and Cobra1 During Mouse Mammary Gland Development. Sci Rep 8:2731
Zanotto-Filho, Alfeu; Rajamanickam, Subapriya; Loranc, Eva et al. (2018) Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells. Cancer Lett 425:101-115
Segovia, Jesus A; Chang, Te-Hung; Winter, Vicki T et al. (2018) NLRP3 Is a Critical Regulator of Inflammation and Innate Immune Cell Response during Mycoplasma pneumoniae Infection. Infect Immun 86:
Donegan, Jennifer J; Boley, Angela M; Lodge, Daniel J (2018) Embryonic stem cell transplants as a therapeutic strategy in a rodent model of autism. Neuropsychopharmacology 43:1789-1798
Vaidya, Anand; Flores, Shahida K; Cheng, Zi-Ming et al. (2018) EPAS1 Mutations and Paragangliomas in Cyanotic Congenital Heart Disease. N Engl J Med 378:1259-1261
Cepeda, Sergio; Cantu, Carolina; Orozco, Stephanie et al. (2018) Age-Associated Decline in Thymic B Cell Expression of Aire and Aire-Dependent Self-Antigens. Cell Rep 22:1276-1287
Snead, Wilton T; Zeno, Wade F; Kago, Grace et al. (2018) BAR scaffolds drive membrane fission by crowding disordered domains. J Cell Biol :
Ramasamy, Kumaraguruparan; Balasubramanian, Sowmya; Manickam, Krishnan et al. (2018) Mycoplasma pneumoniae Community-Acquired Respiratory Distress Syndrome Toxin Uses a Novel KELED Sequence for Retrograde Transport and Subsequent Cytotoxicity. MBio 9:

Showing the most recent 10 out of 989 publications